EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access · CC BY-NC 4.0

Response to the Letter to the Editor on “Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity”

Felix N von Brackel, Mikolaj Bartosik, Oskar Windels, Michael Amling, Ralf Oheim

Osteoporosis International · 2026-10 · 37 (10) · 2769-2770

DOI: 10.1007/s00198-026-08260-7 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Osteoporosis International, online erschienen am 14.10.2026. Verfasst von Felix N von Brackel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Hauptthemen laut MEDLINE: Osteogenesis Imperfecta, Bone Density, Bone Density Conservation Agents, Antibodies, Monoclonal. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We respond to methodological questions raised in a “Letter to the Editor” regarding our retrospective case series on romosozumab treatment in osteogenesis imperfecta (OI). We clarify that the retrospective study design, the rarity of the disease, the small number of cases, and the exploratory nature of the analyses limit the methodological approaches as already acknowledged in our original manuscript. Thus, the primary concern is an inherent limitation of an exploratory study in a rare disease. Nevertheless, these data are helpful, as they generate new hypotheses given the currently very limited clinical data available.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Osteogenesis ImperfectaBone DensityBone Density Conservation AgentsAntibodies, MonoclonalHumansAbsorptiometry, PhotonRetrospective Studies

Substanzen

Bone Density Conservation AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. r.oheim@uke.de.

Zitieren

APA

von Brackel, F. N., Bartosik, M., Windels, O., Amling, M., & Oheim, R. (2026). Response to the Letter to the Editor on “Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity”. Osteoporosis International, 37(10), 2769-2770. https://doi.org/10.1007/s00198-026-08260-7

Vancouver

von Brackel FN, Bartosik M, Windels O, Amling M, Oheim R. Response to the Letter to the Editor on “Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity”. Osteoporosis International. 2026;37(10):2769-2770. doi:10.1007/s00198-026-08260-7

BibTeX
@article{vonBrackel2026,
  author = {von Brackel, Felix N and Bartosik, Mikolaj and Windels, Oskar and Amling, Michael and Oheim, Ralf},
  title = {Response to the Letter to the Editor on “Interpreting romosozumab-associated BMD changes in osteogenesis imperfecta: design, densitometry, and multiplicity”},
  journal = {Osteoporosis International},
  year = {2026},
  volume = {37},
  number = {10},
  pages = {2769--2770},
  doi = {10.1007/s00198-026-08260-7}
}
Kostenlos starten →